Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, UBS Group Analyst Says

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target hoisted by stock analysts at UBS Group from $331.00 to $349.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. UBS Group’s price objective would suggest a potential upside of 34.55% from the company’s previous close.

Several other research firms have also recently issued reports on ALNY. Chardan Capital upped their target price on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a “buy” rating in a research note on Friday. Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Citigroup increased their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a report on Friday, March 21st. Canaccord Genuity Group upped their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Finally, StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $319.17.

Alnylam Pharmaceuticals Trading Up 1.7 %

Shares of NASDAQ ALNY opened at $259.39 on Friday. The company has a market cap of $33.74 billion, a PE ratio of -119.53 and a beta of 0.17. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The firm’s 50 day moving average price is $248.21 and its 200-day moving average price is $254.99. Alnylam Pharmaceuticals has a 52-week low of $144.73 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. During the same quarter last year, the company posted ($0.16) EPS. The company’s revenue was up 20.2% on a year-over-year basis. On average, equities research analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 663 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the sale, the executive vice president now directly owns 14,321 shares in the company, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 1,548 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at $3,017,271.63. This represents a 11.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,392 shares of company stock valued at $1,875,627 in the last three months. 1.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ALNY. Capital World Investors lifted its holdings in shares of Alnylam Pharmaceuticals by 0.6% in the 4th quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company’s stock valued at $3,906,284,000 after acquiring an additional 92,101 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Alnylam Pharmaceuticals by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock worth $2,996,296,000 after purchasing an additional 98,303 shares during the period. Capital Research Global Investors increased its position in shares of Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company’s stock valued at $1,639,767,000 after purchasing an additional 1,724,610 shares during the last quarter. Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. lifted its position in Alnylam Pharmaceuticals by 39.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company’s stock worth $1,031,705,000 after buying an additional 1,245,195 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.